1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A National Cancer Data Base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995 [see commetns].
Cancer. 83:2638–2648. 1998. View Article : Google Scholar
|
4
|
Brassard M, Borget I, Edet-Sanson A, et
al: Long-term follow-up of patients with papillary and follicular
thyroid cancer: a prospective study on 715 patients. J Clin
Endocrinol Metab. 96:1352–1359. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Mazzaferri EL: An overview of the
management of papillary and follicular thyroid carcinoma. Thyroid.
9:421–427. 1999. View Article : Google Scholar : PubMed/NCBI
|
6
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
7
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid N, Differentiated Thyroid Cancer.
Cooper DS, Doherty GM, Haugen BR, et al: Revised American Thyroid
Association management guidelines for patients with thyroid nodules
and differentiated thyroid cancer. Thyroid. 19:1167–1214. 2009.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Schlumberger M, Borget I, Nascimento C,
Brassard M and Leboulleux S: Treatment and follow-up of low-risk
patients with thyroid cancer. Nat Rev Endocrinol. 7:625–628. 2011.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Castagna MG, Brilli L, Pilli T, et al:
Limited value of repeat recombinant human thyrotropin
(rhTSH)-stimulated thyroglobulin testing in differentiated thyroid
carcinoma patients with previous negative rhTSH-stimulated
thyroglobulin and undetectable basal serum thyroglobulin levels. J
Clin Endocrinol Metab. 93:76–81. 2008. View Article : Google Scholar
|
10
|
Kloos RT and Mazzaferri EL: A single
recombinant human thyrotropin-stimulated serum thyroglobulin
measurement predicts differentiated thyroid carcinoma metastases
three to five years later. J Clin Endocrinol Metab. 90:5047–5057.
2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Melo M, Costa G, Ribeiro C, et al:
Stimulated thyroglobulin at recombinant human TSH-aided ablation
predicts disease-free status one year later. J Clin Endocrinol
Metab. 98:4364–4372. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wittekind C, Compton CC, Greene FL and
Sobin LH: TNM residual tumor classification revisited. Cancer.
94:2511–2516. 2002. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kloos RT: Thyroid cancer recurrence in
patients clinically free of disease with undetectable or very low
serum thyroglobulin values. J Clin Endocrinol Metab. 95:5241–5248.
2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Robbins RJ, Chon JT, Fleisher M, Larson SM
and Tuttle RM: Is the serum thyroglobulin response to recombinant
human thyrotropin sufficient, by itself, to monitor for residual
thyroid carcinoma? J Clin Endocrinol Metab. 87:3242–3247. 2002.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Mazzaferri EL and Kloos RT: Is diagnostic
iodine-131 scanning with recombinant human TSH useful in the
follow-up of differentiated thyroid cancer after thyroid ablation?
J Clin Endocrinol Metab. 87:1490–1498. 2002. View Article : Google Scholar : PubMed/NCBI
|
16
|
Giovanella L, Ceriani L, Ghelfo A, et al:
Thyroglobulin assay during thyroxine treatment in low-risk
differentiated thyroid cancer management: comparison with
recombinant human thyrotropin-stimulated assay and imaging
procedures. Clin Chem Lab Med. 44:648–652. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Smallridge RC, Meek SE, Morgan MA, et al:
Monitoring thyroglobulin in a sensitive immunoassay has comparable
sensitivity to recombinant human tsh-stimulated thyroglobulin in
follow-up of thyroid cancer patients. J Clin Endocrinol Metab.
92:82–87. 2007. View Article : Google Scholar
|
18
|
Schlumberger M, Hitzel A, Toubert ME, et
al: Comparison of seven serum thyroglobulin assays in the follow-up
of papillary and follicular thyroid cancer patients. J Clin
Endocrinol Metab. 92:2487–2495. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Nascimento C, Borget I, Al Ghuzlan A, et
al: Persistent disease and recurrence in differentiated thyroid
cancer patients with undetectable postoperative stimulated
thyroglobulin level. Endocr Relat Cancer. 18:R29–R40. 2011.
|
20
|
Pacini F, Molinaro E, Castagna MG, et al:
Recombinant human thyrotropin-stimulated serum thyroglobulin
combined with neck ultrasonography has the highest sensitivity in
monitoring differentiated thyroid carcinoma. J Clin Endocrinol
Metab. 88:3668–3673. 2003. View Article : Google Scholar : PubMed/NCBI
|
21
|
Torlontano M, Crocetti U, Augello G, et
al: Comparative evaluation of recombinant human
thyrotropin-stimulated thyroglobulin levels, 131I whole-body
scintigraphy, and neck ultrasonography in the follow-up of patients
with papillary thyroid microcarcinoma who have not undergone
radioiodine therapy. J Clin Endocrinol Metab. 91:60–63. 2006.
View Article : Google Scholar
|